Press Release

Filed: 25 Aug 2026, 12:18 IST Exchange: NSE Category: Corporate Action — Investment

Natco Pharma Limited invests US$14 million in eGenesis, Inc. via subsidiaries Natco Pharma (Canada) Inc. (US$9.5 million) and Natco Pharma South Africa Proprietary Limited (US$4.5 million) through convertible promissory notes. Total investment now US$22 million. eGenesis develops genome engineering tech for transplantable organs to address organ shortage. Acquisition completion expected by September 30, 2026. Investment aims to support new therapeutic programs for unmet medical needs.

Source: Original filing PDF — view on exchange portal

⚡ You're reading this after the fact — subscribers got it instantly

ISA

Indian Stock Alerts BOT

🚨 NATCOPHARM — Quarterly Results

Revenue: ₹2,35,800 Cr (+12% YoY)

PAT: ₹19,200 Cr (+17% YoY)

EBITDA margin: 16.8%

Board declared ₹10/share dividend. Jio adds 8M subs.

📎 bseindia.com/xml-data/...

🎧 Audio summary ready

✓✓ 6:47 PM

🎧

Instant audio summaries2-min AI concall recap delivered with every earnings alert

📊

20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings

🔍

Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically

⚡

Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add NATCOPHARM to your watchlist — all of this, automated.

14-day Pro trial · No credit card · Cancel anytime

More on Natco Pharma Limited

Important. The summary above is generated automatically from Natco Pharma Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.